Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages
A Kansas Collateral License Agreement is a legal document that outlines the terms and conditions of a partnership between Gentling, Inc. and The University of North Texas Health Science Center. This agreement enables the University to grant Gentling collateral rights to any intellectual property or innovations resulting from their collaborative efforts. The purpose of this collaboration is to promote scientific research, technological advancements, and commercial development in various fields, including biotechnology, pharmaceuticals, genetics, and healthcare. The University, as a leading academic institution, brings its expertise, resources, and research facilities to the table, while Gentling, a renowned biotech company, provides its industry knowledge, technological know-how, and financial support. Key provisions of the Kansas Collateral License Agreement include the obligations of each party, the allocation of intellectual property rights, financial arrangements, and dispute resolution mechanisms. The agreement categorizes the intellectual property as direct, indirect, or shared, depending on the extent to which it is created or utilized by each party. Direct intellectual property refers to inventions, discoveries, and other innovations that are solely produced by either Gentling or the University. In such cases, the owning party retains all rights and may choose to grant the other party a non-exclusive license to use the intellectual property for specific purposes outlined in the agreement. Indirect intellectual property refers to innovations that are developed collaboratively by both Gentling and the University. In these cases, the agreement stipulates that joint ownership and shared rights are established, allowing both parties to utilize and commercialize the intellectual property in line with their respective interests. The Kansas Collateral License Agreement also addresses compensation and royalty arrangements. Gentling may provide financial support to the University to cover research expenses, infrastructure upgrades, or other mutually agreed-upon costs. In return, the University may be entitled to receive royalties or other forms of compensation from Gentling for the utilization or commercialization of jointly owned intellectual property. In case of disputes arising from this agreement, the parties agree to resolve them through arbitration, mediation, or negotiation. This clause ensures that any conflicts can be resolved swiftly, maintaining the continuity and progress of the collaborative relationship. Overall, the Kansas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a framework for their collaboration, outlining the ownership and usage of intellectual property, financial arrangements, and dispute resolution mechanisms. This partnership aims to foster scientific advancements and innovation beneficial to both parties while contributing to the broader fields of biotechnology, pharmaceuticals, genetics, and healthcare.
A Kansas Collateral License Agreement is a legal document that outlines the terms and conditions of a partnership between Gentling, Inc. and The University of North Texas Health Science Center. This agreement enables the University to grant Gentling collateral rights to any intellectual property or innovations resulting from their collaborative efforts. The purpose of this collaboration is to promote scientific research, technological advancements, and commercial development in various fields, including biotechnology, pharmaceuticals, genetics, and healthcare. The University, as a leading academic institution, brings its expertise, resources, and research facilities to the table, while Gentling, a renowned biotech company, provides its industry knowledge, technological know-how, and financial support. Key provisions of the Kansas Collateral License Agreement include the obligations of each party, the allocation of intellectual property rights, financial arrangements, and dispute resolution mechanisms. The agreement categorizes the intellectual property as direct, indirect, or shared, depending on the extent to which it is created or utilized by each party. Direct intellectual property refers to inventions, discoveries, and other innovations that are solely produced by either Gentling or the University. In such cases, the owning party retains all rights and may choose to grant the other party a non-exclusive license to use the intellectual property for specific purposes outlined in the agreement. Indirect intellectual property refers to innovations that are developed collaboratively by both Gentling and the University. In these cases, the agreement stipulates that joint ownership and shared rights are established, allowing both parties to utilize and commercialize the intellectual property in line with their respective interests. The Kansas Collateral License Agreement also addresses compensation and royalty arrangements. Gentling may provide financial support to the University to cover research expenses, infrastructure upgrades, or other mutually agreed-upon costs. In return, the University may be entitled to receive royalties or other forms of compensation from Gentling for the utilization or commercialization of jointly owned intellectual property. In case of disputes arising from this agreement, the parties agree to resolve them through arbitration, mediation, or negotiation. This clause ensures that any conflicts can be resolved swiftly, maintaining the continuity and progress of the collaborative relationship. Overall, the Kansas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a framework for their collaboration, outlining the ownership and usage of intellectual property, financial arrangements, and dispute resolution mechanisms. This partnership aims to foster scientific advancements and innovation beneficial to both parties while contributing to the broader fields of biotechnology, pharmaceuticals, genetics, and healthcare.